SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotime-Nasdaq's best kept secret?
BTIM 0.00010000.0%Nov 5 1:26 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Roof who wrote (885)4/30/1998 11:09:00 PM
From: Wai-Shan Lam  Read Replies (1) of 1432
 
i talked to Biotime investor relations just now - Victoria was the
person i talked to. she said they're not preparing to respond to
arsenio's comments b/c it's false and without basis, and that he's made the same false claims a few months ago already. she said it can't be a coincidence that arsenio is releasing their sell comments again just as Biotime is releasing their clinical results. also she said the statistic test they conducted according to what FDA wanted was only intended to show whether Hextend was any different from the other 2 products, not whether it's better. so the test being statistically insignificant is not saying that Hextend doesn't offer more advantage over the other 2 existing products. i asked Victoria what she thought the main points for Hextend's advantage - she said the fact that Hextend contains a buffer which makes the PH more constant, and electrolytes, and also the fact that it doesn't interfere with clotting as much all make Hextend a better product. she also pointed using plasma expander avoids hepatitis C infection. she said Biotime never made any official sales projection and she had no idea where the $750 million # came from. they have internal projection that's not made public. the point that was very
vague is the $100 price tag - she said Abbott can charge whatever they
think it's the fair price for a superior product. so $100 is not a false #. she said if the market is limited to the existing $30 million then Abbott wouldn't have bothered signing a deal with Biotime. if what they're trying to do is not just to capture part of the $30 million market but to expand the market and take it to the next level...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News